Combined Oxidative Phosphorylation Deficiency Caused by Mutation in GTPBP3

Combined oxidative phosphorylation deficiency caused by mutation in GTPBP3 is a very rare inherited mitochondrial disease. In medical databases it is usually called combined oxidative phosphorylation deficiency 23, or COXPD23, and it happens when both copies of the GTPBP3 gene do not work properly. This gene problem damages the cell’s “power stations” (mitochondria), so the body cannot make enough energy, especially in the heart, brain and muscles.

Combined oxidative phosphorylation deficiency 23 is a very rare genetic mitochondrial disease caused by harmful changes (mutations) in the GTPBP3 gene. This gene helps modify mitochondrial transfer RNA (mt-tRNA), which is needed to build normal proteins inside the mitochondria, the “power plants” of the cell. When GTPBP3 does not work properly, mitochondria cannot make enough energy using the oxidative phosphorylation (OXPHOS) system. This leads to reduced activity of several respiratory chain complexes and high levels of lactic acid in the blood. []

This condition usually starts in babies or young children. Common features include weak muscle tone (hypotonia), heart muscle thickening (hypertrophic cardiomyopathy), developmental delay, seizures, breathing problems, and persistent lactic acidosis. Severity can vary a lot from child to child, even in the same family. The disease is inherited in an autosomal recessive way, which means a child needs two changed copies of the GTPBP3 gene, one from each parent. []

There is no single cure at this time. Treatment focuses on supporting the child’s heart, brain, muscles, breathing and nutrition, and on avoiding things that stress the mitochondria. Doctors often use a mix of vitamins, mitochondrial “cocktails,” careful nutrition, and standard therapies for heart and brain symptoms. Because good studies are rare, most treatments are based on small patient reports and expert opinion, not large clinical trials. []

Other names

Doctors and databases use several names for this same condition. It may be written as combined oxidative phosphorylation deficiency 23, combined oxidative phosphorylation defect type 23, GTPBP3-related combined oxidative phosphorylation deficiency, or simply GTPBP3-associated mitochondrial disease. All these names describe one disorder: an energy-making problem in mitochondria caused by harmful variants in the GTPBP3 gene.

What happens in the body

The GTPBP3 gene gives the recipe for a protein that lives inside mitochondria and helps modify small helper molecules called mitochondrial tRNAs. These tRNAs are needed to build mitochondrial proteins that form the respiratory chain complexes (complexes I–IV), which are key parts of oxidative phosphorylation, the main energy-making system in the cell. When GTPBP3 is faulty, mitochondrial tRNAs are not modified correctly, mitochondrial proteins are not made well, and the oxidative phosphorylation chain works poorly, so cells make less energy and produce too much lactic acid.

Because of this energy failure, high-demand organs like the heart and brain are affected most. Many patients develop hypertrophic cardiomyopathy (thick heart muscle), lactic acidosis (high lactate in blood), and brain problems such as developmental delay, low muscle tone and seizures, often starting in infancy or early childhood.

Types

Although there is only one genetic disease (COXPD23), doctors see different clinical patterns or “types” based on when symptoms start and how severe they are. These are not official separate diseases but useful ways to think about the condition.

1. Severe early-infantile cardio-encephalopathic type
   In this pattern, babies present very early with strong lactic acidosis, severe hypotonia, feeding problems and hypertrophic cardiomyopathy, sometimes with heart failure. Brain imaging may show lesions in basal ganglia, thalamus or brainstem, and some infants may die in early life despite intensive care.

2. Childhood neurologic-dominant type with heart involvement
   In this type, children may first show global developmental delay, ataxic gait, tremor, seizures and learning difficulties. Hypertrophic cardiomyopathy or arrhythmias can be present but sometimes are milder or appear later. Lactic acidosis is usually persistent but may be moderate.

3. Milder adolescent type
   A few reported patients have milder courses, with developmental delay, tremor or seizures and relatively preserved general health, sometimes surviving into the second decade or beyond. Heart disease and lactic acidosis may still be present but are less dramatic.

Causes (mechanisms and risk factors)

Remember that the basic cause is always harmful changes (variants) in both copies of the GTPBP3 gene. The items below explain different ways this can happen and different biological steps that link the gene change to the disease.

1. Biallelic pathogenic variants in GTPBP3
   The direct cause of the disease is having disease-causing variants in both copies of the GTPBP3 gene (biallelic variants), inherited from each parent. With one bad copy you are a healthy carrier; with two bad copies the mitochondrial tRNA modification system fails and disease appears.

2. Homozygous missense variants
   Some patients have the same missense variant (a single amino-acid change) on both alleles. This type of change may leave some protein activity but still weakens mitochondrial tRNA modification enough to cause combined oxidative phosphorylation deficiency.

3. Compound heterozygous missense variants
   Many reported cases have two different missense variants, one from each parent. Together, these two different but harmful changes reduce GTPBP3 function below the level needed for normal mitochondrial translation and energy production.

4. Nonsense variants causing truncated protein
   Nonsense variants introduce a premature stop codon, leading to a shortened or absent GTPBP3 protein. This often causes more severe loss of function and may be associated with early-onset, more severe disease, because almost no functional enzyme is made.

5. Splice-site variants disturbing mRNA splicing
   Some variants affect the borders between exons and introns, disturbing splicing of the GTPBP3 messenger RNA. The resulting abnormal RNA can lead to missing exons or frameshifts, which again produce non-functional protein and trigger combined oxidative phosphorylation deficiency.

6. Frameshift insertions or deletions
   Small insertions or deletions that shift the reading frame of the gene create a series of wrong amino acids followed by a premature stop. This usually severely disrupts the GTPBP3 protein, leading to a strong mitochondrial translation defect.

7. Variants affecting the GTPase domain
   GTPBP3 has a GTP-binding (GTPase) domain that is important for its enzymatic activity. Missense variants inside this domain can reduce its ability to bind or hydrolyze GTP and therefore impair its function in tRNA modification.

8. Variants affecting the tRNA-modification domain
   Other variants lie in regions of GTPBP3 that directly interact with mitochondrial tRNAs or partner protein MTO1. These changes can blunt the formation of the taurine-containing base (τm⁵U) at the wobble position of several mitochondrial tRNAs, blocking accurate mitochondrial protein synthesis.

9. Autosomal recessive inheritance from two carrier parents
   The disease follows an autosomal recessive pattern. When both parents silently carry one mutated GTPBP3 allele, each child has a 25% chance to be affected, 50% chance to be a carrier, and 25% chance to inherit two normal alleles. Consanguineous parents raise the chance that both carry the same rare variant.

10. Large deletions or duplications involving GTPBP3
    Very rarely, structural changes such as deletions or duplications that remove all or part of the GTPBP3 gene can also cause the disease, because no full-length functional protein is produced. Such changes are detected by copy-number analysis or genome sequencing.

11. Defective taurine modification of mitochondrial tRNAs
    GTPBP3 normally helps add a taurine-containing modification (5-taurinomethyluridine) to specific mitochondrial tRNAs. When GTPBP3 is mutated, this taurine modification is reduced or absent, so the tRNAs cannot decode mitochondrial genes efficiently during translation.

12. Global mitochondrial translation defect
    Due to abnormal tRNA modification, the mitochondrial ribosome struggles to translate mitochondrial mRNAs into protein. The rate and accuracy of making mitochondrial proteins fall, leading to fewer functional subunits of respiratory chain complexes.

13. Combined deficiency of respiratory chain complexes I and IV
    Enzyme studies in muscle biopsies of patients often show reduced activity in complexes I and IV of the mitochondrial respiratory chain. These complexes are key for oxidative phosphorylation, so their combined deficiency sharply reduces ATP production.

14. Chronic lactic acidosis from impaired oxidative phosphorylation
    Because oxidative phosphorylation is weak, cells rely more on anaerobic glycolysis, which makes lactate. This leads to chronically high lactate levels in blood and sometimes cerebrospinal fluid, which can cause acidosis and contribute to fatigue, vomiting and rapid breathing.

15. Heart muscle susceptibility to energy failure
    The heart needs constant high energy. In COXPD23 the reduced ATP production makes the heart muscle cells enlarge and thicken (hypertrophy) as they try to compensate, leading to hypertrophic cardiomyopathy and sometimes heart failure and arrhythmias.

16. Brain vulnerability to mitochondrial dysfunction
    The brain also uses a lot of energy. MRI in several patients shows lesions in deep brain structures such as the thalamus, basal ganglia and brainstem, likely due to local energy failure, which explains hypotonia, seizures and developmental delay.

17. Possible modifying variants in other mitochondrial genes
    Some studies suggest that variants in other mitochondrial translation genes like MTO1 may modify how severe GTPBP3-related disease is, although they are not the primary cause. These background genes can influence how the defective tRNA modification pathway behaves.

18. Physiological stress as a trigger for decompensation
    Infections, fever, surgery or fasting do not cause the genetic disease but increase the body’s energy needs. In a child with COXPD23, this can trigger metabolic crises with worsening lactic acidosis, breathing problems or heart failure.

19. Possible role of taurine availability
    Experimental work on taurine-related tRNA modifications suggests that low taurine levels may worsen mitochondrial translation defects, although direct proof in COXPD23 is limited. Thus, taurine status might modify symptom severity but does not replace the central genetic cause.

20. De novo (new) GTPBP3 variants in rare cases
    Most patients inherit variants from carrier parents, but in theory a pathogenic variant could also appear “de novo” in the egg or sperm. If the other allele also carries a pathogenic variant, the child may still develop COXPD23, even if one parent is not a carrier.

Symptoms (main clinical features)

1. Lactic acidosis
   Many children have high levels of lactic acid in their blood and sometimes in cerebrospinal fluid. This can cause fast breathing, vomiting, poor feeding and general tiredness, and it may get worse during infections or stress.

2. Hypertrophic cardiomyopathy
   The heart muscle becomes abnormally thick, especially in the left ventricle. This may cause shortness of breath, poor feeding, sweating with feeds, or heart failure signs in infants and children.

3. Heart failure and arrhythmias
   In severe cases, the thickened heart cannot pump well, leading to heart failure with swelling, fast breathing and poor circulation. Abnormal heart rhythms (arrhythmias) can also occur and may be life-threatening if not recognized and treated.

4. Global developmental delay
   Many children reach motor and language milestones later than normal. They may sit, walk or speak later and may need ongoing physiotherapy and special educational support.

5. Hypotonia (low muscle tone)
   Babies can feel “floppy” when held. They may have trouble lifting their head, rolling, or sitting without support, because their muscles and motor control are weak.

6. Seizures and epilepsy
   Some patients develop seizures, which may present as stiffening, jerking, staring spells or loss of awareness. These seizures are linked to brain involvement and may need anti-seizure medication.

7. Encephalopathy (brain dysfunction)
   Encephalopathy means global brain dysfunction. Children may show confusion, reduced consciousness, abnormal movements, or worsening developmental skills during metabolic crises, often with MRI lesions in deep brain structures.

8. Feeding difficulties and failure to thrive
   Because of low energy and sometimes poor coordination of sucking and swallowing, infants may feed slowly, tire during feeds, or vomit often. They may gain weight poorly and need tube feeding support.

9. Shortness of breath and dyspnea
   Children can breathe fast or appear short of breath due to both lactic acidosis and heart dysfunction. In severe cases they may require oxygen or ventilatory support in hospital.

10. Fatigue and exercise intolerance
    Older children may tire quickly with walking, running or climbing stairs. They may avoid physical activities compared to peers because their muscles and heart cannot keep up with energy demands.

11. Tremor and ataxic gait
    Some patients show tremor of the hands and an unsteady, wide-based walk (ataxia). These signs reflect cerebellar or other brain involvement due to mitochondrial dysfunction.

12. Intellectual disability or learning difficulties
    Because of chronic brain involvement, many children have lower than expected IQ or learning problems. They may need special education, speech therapy and other developmental services.

13. Visual impairment
    Some cases report poor visual tracking, reduced visual acuity or other visual problems, possibly related to optic nerve or brain pathway involvement.

14. Hearing problems (in some patients)
    A few patients with GTPBP3 variants have hearing loss, and GTPBP3 is also known to modify the severity of certain mitochondrial deafness mutations. Hearing should therefore be checked regularly.

15. Growth delay and underweight
    Because of chronic illness, poor intake and high energy use, some children remain smaller and lighter than peers, even with careful nutritional support.

Diagnostic tests

Below are 20 tests that doctors commonly use to suspect, confirm and understand COXPD23. They are grouped by type, but in real life they are chosen case-by-case.

Physical examination

1. General physical and growth examination (physical exam)
   The doctor checks weight, height, head size, body proportions, breathing, skin color and overall appearance. Poor growth, small size for age or signs of chronic illness can suggest a long-standing metabolic or mitochondrial problem.

2. Detailed neurologic examination (physical exam)
   The neurologist looks at muscle tone, strength, reflexes, eye movements and coordination. Findings such as hypotonia, delayed reflexes or abnormal movements support involvement of the central nervous system in a mitochondrial disease.

3. Cardiovascular examination (physical exam)
   The clinician listens to heart sounds, checks for murmurs, gallop rhythm, extra sounds, and looks for signs of heart failure such as leg swelling, liver enlargement or fast breathing. These findings may suggest hypertrophic cardiomyopathy and guide further cardiac tests.

Manual and bedside functional tests

4. Manual muscle strength testing (manual test)
   The doctor asks the child to push or pull against resistance, or tests anti-gravity movements. Weakness in the limbs, especially with fatigue, can point toward a systemic muscle energy problem like mitochondrial disease.

5. Manual assessment of tone and reflexes (manual test)
   By passively moving the limbs and tapping tendons, the examiner can feel low tone (floppiness) or other abnormalities. Reduced tone and altered reflexes are common in children with COXPD23 and help classify the neurologic involvement.

6. Developmental milestone assessment scales (manual / observational test)
   Tools like the Bayley or Denver scales use simple tasks (sitting, walking, saying words, grasping toys) to measure development. Delays across several areas support the idea of a global encephalopathy, often seen in mitochondrial disorders.

7. Bedside feeding and swallowing evaluation (manual test)
   A clinician or speech therapist watches how the child swallows liquids and food, and checks for choking, coughing or very slow feeding. Feeding difficulty and fatigue with sucking are common early signs and can guide decisions about tube feeding.

Laboratory and pathological tests

8. Serum lactate and pyruvate levels (lab test)
   Blood tests measure lactate and sometimes pyruvate. High lactate, especially with an increased lactate-to-pyruvate ratio, suggests impaired oxidative phosphorylation. In COXPD23, lactic acidosis is a frequent and important biochemical clue.

9. Arterial or capillary blood gas analysis (lab test)
   Blood gas testing looks at pH, bicarbonate and carbon dioxide. In lactic acidosis, the pH is low and bicarbonate is low, showing metabolic acidosis. This helps assess the severity of metabolic disturbance and guides emergency treatment.

10. Basic metabolic panel, liver enzymes and creatine kinase (lab test)
    These tests measure electrolytes, kidney function, liver enzymes and muscle enzyme CK. Abnormal values can show the impact of mitochondrial disease on liver and muscle and help exclude other metabolic disorders.

11. Plasma amino acids, acylcarnitine profile and urine organic acids (lab test)
    These metabolic screening tests look for patterns typical of various inherited metabolic diseases. In COXPD23 they may be normal or show nonspecific changes, but they are important to rule out other treatable metabolic conditions.

12. Cerebrospinal fluid (CSF) lactate and protein analysis (lab test)
    A lumbar puncture can measure lactate and protein in CSF. Elevated CSF lactate and sometimes increased protein support mitochondrial encephalopathy and help differentiate it from other brain diseases.

13. Muscle biopsy respiratory chain enzyme assays (pathological test)
    A small piece of muscle is taken and tested for the activity of respiratory chain complexes I–IV. In COXPD23, complex I and IV activities are often reduced, confirming a combined oxidative phosphorylation defect at the tissue level.

14. Muscle biopsy histology and electron microscopy (pathological test)
    Under the microscope, muscle may show ragged-red fibers, abnormal mitochondria or other structural changes. Electron microscopy can reveal swollen or irregular mitochondria, which support the diagnosis of a mitochondrial myopathy.

15. Targeted GTPBP3 gene sequencing (genetic lab test)
    Once a mitochondrial disease is suspected, doctors can sequence the GTPBP3 gene to look for pathogenic variants. Finding biallelic disease-causing variants confirms that the combined oxidative phosphorylation defect is due to GTPBP3 mutations (COXPD23).

16. Whole-exome or whole-genome sequencing (genetic lab test)
    In many patients, a broad sequencing test is used first. It examines most or all genes at once and can detect GTPBP3 variants even when the specific diagnosis is not suspected. This is now a key tool for diagnosing rare mitochondrial diseases.

Electrodiagnostic tests

17. Electrocardiogram (ECG) (electrodiagnostic test)
    An ECG records the heart’s electrical activity. It can show conduction problems, arrhythmias or repolarization changes associated with hypertrophic cardiomyopathy, helping cardiologists plan monitoring and treatment.

18. Electroencephalogram (EEG) (electrodiagnostic test)
    An EEG measures brain electrical activity and is used in children with seizures or suspected encephalopathy. It can show epileptic discharges or slowing, supporting the diagnosis of a diffuse brain disorder like mitochondrial encephalopathy.

Imaging tests

19. Brain MRI (imaging test)
    MRI of the brain often shows abnormal signal in deep structures such as basal ganglia, thalamus and brainstem in COXPD23. These changes are typical for mitochondrial encephalopathy and help distinguish it from other brain diseases.

20. Echocardiography (heart ultrasound) (imaging test)
    Echocardiography uses ultrasound to visualise the heart. It can show thickened heart walls, reduced pumping function or outflow obstruction, which confirm hypertrophic cardiomyopathy and guide cardiac management in affected children.

Non-pharmacological (non-drug) treatments

Below are common supportive therapies that specialists may consider for children with GTPBP3-related combined OXPHOS deficiency. These are examples, not personal medical advice.

1. Energy management and pacing

Daily activities are planned to match the child’s limited energy. Parents and therapists help the child take frequent rests, avoid long fasting, and spread tasks across the day. This reduces sudden energy crashes, lactic acidosis and heart strain. It also helps prevent repeated hospital visits during infections or stressful events. []

2. Specialized nutrition and feeding support

A dietitian experienced in mitochondrial disease adjusts calories, proteins, and fats to give enough energy without overloading the child’s weak mitochondria. The team watches for poor weight gain, vomiting or swallowing problems. In some children, a feeding tube is used to give safe and regular nutrition and medicines. []

3. Management of lactic acidosis triggers

Parents learn to avoid long periods without food, severe dehydration, and uncontrolled fever, which can push lactic acid higher. Early treatment of infections, careful IV fluids, and sometimes temporary extra calories during illness are used to protect the child from metabolic crises and organ damage. []

4. Physiotherapy for muscle weakness and hypotonia

Gentle physiotherapy helps keep muscles active without over-tiring the child. Exercises focus on posture, joint range, and safe movement. The goal is to maintain mobility, delay contractures, and improve breathing mechanics by strengthening trunk muscles. Therapy is always paced to avoid post-exercise worsening. []

5. Occupational therapy for daily skills

Occupational therapists teach ways to save energy when dressing, bathing, writing or playing. They may recommend adapted chairs, utensils, and bathroom supports. This helps the child stay as independent as possible and reduces stress on weak muscles and the heart. []

6. Speech and swallowing therapy

If the child has feeding, swallowing or speech problems, a speech-language therapist assesses them. The therapist can teach safer swallowing techniques, suggest thicker liquids or altered food textures, and support communication, including communication devices if needed. This reduces the risk of aspiration and improves quality of life. []

7. Cardiac monitoring and non-surgical heart support

Children with hypertrophic cardiomyopathy need regular heart checks (ECG, echocardiography) to monitor pumping function, rhythm, and wall thickness. Early detection of changes allows timely medical adjustments and planning for advanced therapies if needed. Avoiding dehydration and severe anemia also protects the heart. []

8. Respiratory physiotherapy and non-invasive ventilation

Weak respiratory muscles and heart problems can cause low oxygen and CO₂ retention. Respiratory therapy uses breathing exercises, chest physiotherapy and, when needed, non-invasive ventilation (for example, BiPAP at night). This supports gas exchange, prevents infections and improves sleep and daytime alertness. []

9. Early developmental and educational support

Early intervention programs provide physical, occupational, speech, and cognitive stimulation. Adapting school programs with rest breaks, special seating, and individual support helps children reach their best possible learning and social level despite fatigue and physical limits. []

10. Vision and hearing support

Some children have visual impairment or hearing loss. Regular checks and early use of glasses, low-vision aids, or hearing aids support communication and learning. Teachers and families can adapt lighting, text size, seating and classroom noise to help the child participate. []

11. Seizure safety planning

Families learn how to recognize seizures early, how to protect the child from injury during an event, and when to seek emergency help. Schools and caregivers receive clear written seizure action plans. This does not cure seizures but reduces harm and anxiety for the family. []

12. Infection prevention and vaccination

Routine vaccinations, good hand hygiene, and quick treatment of common infections are essential. Infections increase metabolic stress and lactic acidosis. Vaccines for influenza, pneumococcus and others are usually recommended unless there is a specific medical reason not to give them. []

13. Temperature and stress management

High fever, extreme cold, or intense emotional stress can trigger metabolic crises in mitochondrial disease. Families are taught to treat fever early, avoid extreme temperatures when possible, and use calming routines to help the child handle stress and medical procedures. []

14. Avoidance of mitochondrial-toxic medicines

Some medicines, such as valproate in certain mitochondrial disorders, can worsen liver or mitochondrial function. The care team keeps an updated “avoid list” and coordinates with all doctors so that safer alternatives are used whenever possible. []

15. Psychological and family support

Chronic, life-limiting illnesses cause strong emotional stress for children and families. Psychologists, social workers and support groups help families cope, plan, grieve, and still find normal joys in daily life. Good mental health support is a key part of care. []

16. Palliative and symptom-focused care

Palliative care focuses on comfort, symptom relief, and family goals at any stage of serious illness, not only at the end of life. It helps manage pain, breathlessness, feeding issues and difficult decisions, while respecting the family’s values and culture. []

17. Assistive mobility devices

Wheelchairs, walkers, standing frames, and customized seating reduce falls, protect joints, and save energy. Mobility aids are adjusted as the child grows, helping them participate in school and family life as much as possible. []

18. Orthopedic management of contractures and scoliosis

Regular checks for spine curvature and joint contractures allow early treatment with stretches, splints, and sometimes braces. Good posture supports breathing and reduces discomfort. In severe cases, surgical options may be discussed with the family. []

19. Genetic counseling for the family

Genetic counselors explain how GTPBP3 mutations are inherited, the risk for future pregnancies, and options like carrier testing or prenatal diagnosis. This helps families make informed reproductive decisions and understand the condition better. []

20. Care coordination in a specialized center

Because this disease involves heart, brain, muscles and metabolism, care is best coordinated by a multidisciplinary center with mitochondrial expertise. Regular team reviews keep treatments aligned and reduce conflicting advice from different specialists. []

---

Drug treatments (supportive and symptom-based)

Very important: there are no drugs currently approved specifically to cure or directly treat GTPBP3-related combined OXPHOS deficiency. Most medicines listed here are used off-label to manage symptoms seen in many mitochondrial diseases, based on small studies or expert practice. Doses are always individualized by specialists; this text is not a dosing guide.

1. Levo-carnitine (CARNITOR®)

Levo-carnitine is used to treat carnitine deficiency and support fatty-acid transport into mitochondria. FDA labels describe its use in inborn errors of metabolism and dialysis patients. In mitochondrial disorders, it may be used to improve energy use and help remove toxic fatty-acid products. The doctor adjusts the dose to weight and kidney function and monitors for side effects such as diarrhea or fishy body odor. []

2. Standard heart-failure medicines (ACE inhibitors, beta-blockers)

Children with hypertrophic cardiomyopathy may receive standard heart-failure drugs like ACE inhibitors or beta-blockers, according to pediatric cardiology guidelines. These medicines reduce heart workload, improve pumping function, and lower arrhythmia risk. Doses start low and are slowly increased while monitoring blood pressure, heart rate and kidney function. []

3. Diuretics for fluid overload

If the heart cannot pump well, fluid can build up in the lungs and legs. Diuretics (water tablets) help the body remove extra salt and water through the kidneys, easing breathing and swelling. Doctors monitor electrolytes and kidney function so the medicine does not cause dehydration or low potassium. []

4. Anti-arrhythmic medicines

Some children with cardiomyopathy develop abnormal heart rhythms. Anti-arrhythmic drugs may be used to stabilize rhythm and reduce fainting or sudden cardiac events. Choice of drug is very individual, as some anti-arrhythmics can worsen mitochondrial function or interact with other medicines. []

5. Antiepileptic drugs (for seizures)

Seizures are treated with modern antiepileptic drugs chosen to minimize mitochondrial toxicity. Experts usually avoid valproate in primary mitochondrial disease when possible. Medicines like levetiracetam or others may be preferred because they have fewer mitochondrial side effects. Doctors slowly adjust doses based on seizure control and side-effect profile. []

6. Intravenous glucose and fluids during crises

During acute metabolic decompensation, IV glucose and carefully balanced fluids are used in hospital to provide immediate energy and support circulation. This is not a routine daily drug but an emergency treatment protocol that can reduce lactic acidosis and protect organs. []

7. Bicarbonate for severe lactic acidosis (selected cases)

In some life-threatening situations with very low blood pH, IV bicarbonate may be given to correct acidosis temporarily. This is done only under close intensive-care monitoring, because too much bicarbonate can worsen CO₂ levels or cause fluid and electrolyte problems. []

8. Anti-spasticity medicines

If the child develops increased muscle tone, spasticity, or painful muscle cramps, medicines such as baclofen may be used to relax muscles. They are started at low doses and adjusted to reduce stiffness while avoiding too much sleepiness or weakness. []

9. Prokinetic and anti-reflux drugs

Stomach and gut problems, such as reflux and slow gastric emptying, are common in mitochondrial disease. Prokinetic drugs and acid-suppressing medicines can reduce vomiting, improve feeding tolerance, and protect the esophagus from acid damage. []

10. Pain medicines

Children may need pain control for headaches, muscle pain or procedures. Doctors choose pain medicines with low mitochondrial toxicity and adjust dose to age and weight. Non-drug methods (rest, physical therapy, relaxation) are often used together with medicines. []

11. Antibiotics for infections

Because infections can trigger crises, doctors treat bacterial infections promptly with appropriate antibiotics. Choice of antibiotic depends on the infection type and local guidelines, while avoiding medicines known to harm mitochondria when alternatives exist. []

12. Medications for heart-transplant or device care

If a child receives a heart transplant or mechanical heart support, they need immunosuppressive and supportive drugs according to transplant protocols. These are highly specialized treatments managed in large centers and tailored to each child. []

(Because of space limits and the lack of disease-specific evidence, more individual drug names are not listed here. Most additional medicines are standard treatments for heart, seizure, nutrition or infection problems, adjusted very carefully for each child.)

---

Dietary molecular supplements

Supplements below are often used as part of a “mitochondrial cocktail.” Evidence is mixed and mostly from small studies, but they are widely discussed in expert reviews. Always used under specialist supervision.

1. Coenzyme Q10 (ubiquinone / ubiquinol)

CoQ10 is a key part of the electron transport chain, carrying electrons between complexes I/II and III. In mitochondrial disorders, extra CoQ10 may improve electron flow and support ATP production. Reviews suggest it can help some patients with mitochondrial disease or primary CoQ10 deficiency, although results vary. Doses and forms (ubiquinol vs ubiquinone) are chosen by specialists and adjusted over time. []

2. Riboflavin (vitamin B2)

Riboflavin is needed to form FAD and FMN, important cofactors for several respiratory chain enzymes. High-dose riboflavin is frequently used in mitochondrial cocktails and has shown benefit in some mitochondrial and metabolic disorders. Specialists monitor liver function and response. []

3. Thiamine (vitamin B1)

Thiamine is a cofactor for pyruvate dehydrogenase and other enzymes that feed into the Krebs cycle. Extra thiamine may help reduce pyruvate build-up and lactic acidosis in some mitochondrial and metabolic diseases. It is relatively safe, but high doses should still be supervised. []

4. Vitamin C (ascorbic acid)

Vitamin C is an antioxidant that can help protect cell membranes and mitochondrial components from oxidative stress. It is often added to mitochondrial cocktails together with CoQ10 and B vitamins. Evidence is limited but safety is generally good at supervised doses. []

5. Vitamin E (tocopherols / tocotrienols)

Vitamin E is a fat-soluble antioxidant that protects cell membranes and mitochondrial lipids from damage by free radicals. It may be combined with vitamin C and CoQ10 in some protocols. Doctors monitor fat-soluble vitamin levels to avoid deficiency or excess. []

6. Alpha-lipoic acid

Alpha-lipoic acid is an antioxidant and a cofactor in mitochondrial enzyme complexes, including pyruvate dehydrogenase. Experimental work suggests it may improve mitochondrial redox balance. It is sometimes used in mitochondrial cocktails, with careful dose selection. []

7. Creatine

Creatine helps buffer energy in muscle cells by storing phosphates that can rapidly regenerate ATP. Supplementation has been explored in some neuromuscular and mitochondrial conditions to improve muscle strength or reduce fatigue, though data are mixed. []

8. L-arginine

L-arginine is a precursor for nitric oxide and may improve blood flow in small vessels. In some mitochondrial conditions like MELAS, it has been used experimentally to reduce stroke-like episodes. In GTPBP3-related disease, its use would be considered individually by specialists. []

9. Nicotinamide / NAD⁺ precursors

Compounds that support NAD⁺ (like nicotinamide or nicotinamide riboside) may help mitochondrial enzymes that need NAD⁺ to function. Research is ongoing, and use in children with primary mitochondrial disorders is still experimental and specialist-guided. []

10. Triheptanoin or medium-chain triglycerides (MCTs)

Special fats such as triheptanoin and MCT oils can provide alternative fuel that may be easier for damaged mitochondria to use. They can supply both energy and anaplerotic substrates for the Krebs cycle. Use is highly individualized and monitored by metabolic dietitians. []

---

Immunity-booster / regenerative / stem-cell–related” drug approaches

These are research or advanced therapies, not routine care. Many are still in trials.

1. Mitochondria-targeted antioxidants (for example, elamipretide)

New drugs are being developed that go directly to mitochondria and protect their membranes or improve electron transport. Agents like elamipretide have shown promise in early studies for some mitochondrial diseases but remain investigational. []

2. PPAR agonists (for example, bezafibrate – experimental use)

Some research tests PPAR agonists to increase mitochondrial biogenesis and improve fatty-acid metabolism. These medicines are approved for other conditions (such as lipid disorders), but their use in primary mitochondrial disease is experimental and must be done only in trials or under strict specialist control. []

3. Vatiquinone and similar redox-modulating agents

Redox-modulating drugs like vatiquinone are designed to reduce oxidative damage and improve mitochondrial function. Clinical trials are ongoing in specific mitochondrial syndromes. Evidence for GTPBP3-related disease is not yet available. []

4. Hematopoietic stem cell transplantation (very selected cases)

In some mitochondrial disorders with severe bone-marrow involvement, stem cell transplantation has been explored. For GTPBP3-related combined OXPHOS deficiency, this is not standard and would be considered only in exceptional research settings because of high risk. []

5. Gene-therapy and vector-based approaches

Experimental gene-therapy strategies aim to deliver healthy copies of mitochondrial or nuclear genes using viral or non-viral vectors. For GTPBP3, such therapies are still at a research stage, with work mainly in lab models rather than children. []

6. General immune support (vaccines, good nutrition, infection control)

Instead of “immune-booster pills,” the most evidence-based way to protect immunity in mitochondrial disease is full vaccination, adequate sleep and nutrition, and very quick treatment of infections. This protects fragile organs from extra stress and reduces hospitalizations. []

---

Surgeries and procedures

1. Gastrostomy tube placement

When a child cannot eat enough by mouth or has unsafe swallowing, a small feeding tube is placed through the abdominal wall into the stomach. This allows reliable delivery of food, water and medicines, reduces aspiration risk, and supports growth. []

2. Cardiac device implantation (pacemaker / ICD)

If dangerous heart rhythm problems occur, a pacemaker or implantable cardioverter-defibrillator (ICD) may be placed. These devices monitor the heart and give small electrical impulses or shocks to maintain safe rhythm and prevent sudden cardiac death. []

3. Heart transplant

In very severe cardiomyopathy that does not respond to medicines or devices, heart transplant may be considered in specialized centers. This is a major operation with long-term immunosuppression, and eligibility depends on many factors including other organ involvement. []

4. Spinal surgery for severe scoliosis

If scoliosis becomes severe and affects breathing or sitting balance, orthopedic surgeons may correct and stabilize the spine. The aim is to improve posture, comfort, and lung function. This is carefully weighed against surgical risk in fragile children. []

5. Tracheostomy and long-term ventilation

In some children with very weak breathing muscles, a tracheostomy (opening in the neck into the windpipe) may be created for more stable long-term ventilation and airway care. It can make suctioning easier and allow some children to go home from intensive care. []

---

Prevention strategie

You cannot fully prevent a genetic GTPBP3 mutation, but you can try to prevent or reduce complications:

1. Early treatment of infections and fever.

2. Avoiding long fasting; using frequent meals and snacks.

3. Keeping vaccinations up to date.

4. Avoiding medicines known to harm mitochondria when possible.

5. Careful planning of anesthesia and surgery in experienced centers.

6. Good everyday nutrition and hydration.

7. Regular follow-up with mitochondrial and cardiac specialists.

8. Prompt management of seizures and breathing problems.

9. Good sleep and stress-reduction routines for the child.

10. Genetic counseling for future pregnancies in the family.

[]

---

What to eat and what to avoid (general ideas)

A metabolic or mitochondrial dietitian should design the exact diet, but some general principles are used in many children with mitochondrial disorders.

What to eat

Doctors usually encourage a balanced diet with enough calories, moderate protein, and an appropriate mix of fats and carbohydrates. Frequent meals and snacks help prevent low blood sugar and reduce lactic acid build-up. Foods rich in natural antioxidants and vitamins—such as fruits, vegetables, and whole grains—can support overall health. In some cases, slightly higher fat or special oils (like MCTs) are added, but this is highly individual. []

What to avoid

Very long fasting, crash diets, and extreme low-carb or high-protein diets are usually avoided because they can increase metabolic stress. Excess sugar drinks, deep-fried foods, and very processed foods are limited as they give “empty” calories without useful nutrients. Grapefruit or other foods that interact with certain medicines may also need caution. Any big diet change should be checked with the child’s metabolic team. []

---

When to see a doctor urgently

Families should seek urgent medical care if a child with GTPBP3-related combined OXPHOS deficiency has signs like rapid breathing, severe vomiting, unusual sleepiness, seizures, chest pain, fainting, new or fast swelling, or any sudden change in behavior or consciousness. These can be signs of lactic acidosis, heart problems, infection or brain involvement. []

Routine visits to a mitochondrial or metabolic specialist, cardiologist, neurologist and dietitian are also important, even when the child seems stable. Regular monitoring of heart function, growth, development and lab tests allows early adjustment of therapies and helps prevent some complications. []

---

Frequently asked questions (FAQs)

1. Is combined oxidative phosphorylation deficiency 23 caused by GTPBP3 mutation common?
No. It is an ultra-rare disease, with fewer than one in a million people affected worldwide. Very few patients have been reported in the medical literature. []

2. What organs are usually affected?
The heart (hypertrophic cardiomyopathy), brain (developmental delay, seizures), muscles (weakness, hypotonia) and metabolism (lactic acidosis) are most often involved, but severity varies widely. []

3. How is the diagnosis made?
Doctors use clinical examination, blood and urine tests (including lactate), brain and heart imaging, muscle or fibroblast studies of the respiratory chain, and finally genetic testing to confirm GTPBP3 mutations. []

4. Is there a cure?
There is no cure yet. Treatment is supportive: protecting the heart and brain, improving energy use, preventing crises, and maximizing quality of life. Research into new therapies is ongoing. []

5. Do mitochondrial “cocktails” work?
Vitamins and supplements like CoQ10, riboflavin and others are widely used, but strong trial data are limited. Some patients improve, others do not. Doctors decide case by case. []

6. Can children with this condition go to school?
Many children can attend school with extra support, rest breaks, and adaptations. The exact plan depends on the child’s energy level, learning needs and medical stability. []

7. Is exercise safe?
Gentle, carefully paced activity under physiotherapy guidance can help maintain strength and avoid contractures. Over-exertion is avoided because it can worsen lactic acidosis and fatigue. []

8. Can this disease get worse suddenly?
Yes. Infections, surgery, dehydration or severe stress can cause sudden worsening with lactic acidosis, heart failure or seizures. Families need clear emergency plans from their doctors. []

9. Are brothers and sisters at risk?
Because the disease is autosomal recessive, each full sibling has a 25% chance of being affected, 50% chance of being a carrier, and 25% chance of having no mutation, if both parents are carriers. []

10. Can adults have this disease?
Most cases start in infancy or childhood, but milder or later-onset cases may be under-recognized. Adult presentations are still being studied. []

11. Is pregnancy safe for mothers who are carriers?
Female carriers are usually healthy but still need genetic counseling. Pregnancy is possible, but families may want to discuss reproductive options and prenatal or preimplantation testing. []

12. Are there clinical trials for this condition?
Some trials for general mitochondrial disease, new antioxidants and gene-based therapies may accept patients with GTPBP3 mutations, but availability depends on country and study design. []

13. Does diet alone control the disease?
No. Diet can help reduce crises and support growth but cannot correct the genetic defect. It is only one part of a full treatment plan. []

14. Should families avoid all vaccines?
Generally no. Most experts recommend vaccines to reduce infection risk, which can trigger metabolic decompensation. Any special concerns should be discussed with the metabolic team. []

15. Where should families get care?
Ideally, care is provided in or coordinated by a center with experience in mitochondrial and metabolic diseases, working with local doctors, therapists and schools. []

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: February 20, 2025.